awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26864870-BF7E5CCC-D2B4-44CF-8E69-B0C6AC96050E
Q26864870-BF7E5CCC-D2B4-44CF-8E69-B0C6AC96050E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26864870-BF7E5CCC-D2B4-44CF-8E69-B0C6AC96050E
Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies
P2860
Q26864870-BF7E5CCC-D2B4-44CF-8E69-B0C6AC96050E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26864870-BF7E5CCC-D2B4-44CF-8E69-B0C6AC96050E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
239eabeaa1e90035a1e24a8f6a242e9f6f92b33c
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer